Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:23:22 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:BCLI - BRAINSTROM CELL THERAPEUTICS - https://www.brainstorm-cell.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCLI - Qnot subscribed0.5775-0.006-1.05.93100.5553  0.62  0.55511.926  0.52113:39:35Dec 1615 min RT 2¢

Recent Trades - All 10 today
Time ETExPriceChangeVolume
13:39:35Q0.5775-0.006200
13:13:34Q0.5595-0.024311
11:30:17Q0.58-0.0035116
11:30:17Q0.58750.004116
11:25:58Q0.56-0.0235754
10:14:48Q0.5551-0.0284140
10:08:35Q0.5696-0.01392,853
09:43:50Q0.573207-0.010293500
09:38:48Q0.620.0365157
09:30:02Q0.5553-0.0282800

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-16 11:53U:BCLINews ReleaseBeyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
2025-11-14 16:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
2025-08-14 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-08 07:00U:BCLINews ReleaseBrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
2025-07-17 16:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
2025-07-08 07:00U:BCLINews ReleaseFDA Review of Citizen Petition Offers a Fresh Look at NurOwn(TM)'s Evidence of Treatment Effectiveness
2025-06-16 08:30U:BCLINews ReleaseBrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn(TM)
2025-05-27 07:00U:BCLINews ReleaseBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn(TM) Phase 3b ALS Clinical Trials
2025-05-19 07:00U:BCLINews ReleaseBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(TM) for ALS
2025-05-15 16:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-15 07:30U:BCLINews ReleaseBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
2025-05-07 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
2025-05-06 07:00U:BCLINews ReleaseBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
2025-04-29 06:30U:BCLINews ReleaseBrainStorm's NurOwn(TM) Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
2025-04-10 07:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(TM) in ALS
2025-03-31 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-26 08:15U:BCLINews ReleaseBrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
2025-03-24 07:00U:BCLINews ReleaseBrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update